The study, released in the peer-reviewed journal Sleep, was conducted by the Johns Hopkins Bloomberg School of Public Health.
The study is considered to be the first of its kind aimed at psychological distress caused by the coronavirus.
New research has identified functional connectivities in the brain that mediate the association between depressive symptoms and poor sleep quality.
They found that the prevalence rate of BZD prescription increased from 0.81 per 100 inhabitants in 2006 to 0.99 per 100 inhabitants in 2013.
“The relation between depression and sleep has been observed more than one hundred years, and now we have identified the neural mechanisms of how they are connected for the first time."